Clovis Oncology's Rubraca Hits Primary Goal In Prostate Cancer Settings
October 03, 2022 at 13:35 PM EDT
Clovis Oncology Inc(NASDAQ: CLVS)announced topline datafrom the Phase 3 TRITON3 trial, demonstrating that Rubraca ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.